A focus on cell line development: Accelerating antibody DNA to IND timelines without negatively impacting quality

This week's Fierce Biotech Research is brought to you by Lonza.

Complimentary White Paper Download

Hi E, check out this Fierce White Paper we think you'll like:

A focus on cell line development: Accelerating antibody DNA to IND timelines without negatively impacting quality

Novel antibody-based therapeutics have revolutionized healthcare and are a prominent feature on top-selling pharmaceutical lists. As antibody engineering and manufacturing technologies improve, previously untreatable diseases can be targeted with increased speed and efficiency. Creating a pathway that balances cost, speed and risk for therapeutic antibody development is crucial to successful and timely approval of new therapeutics.

In this whitepaper, discover how to: